Evidence map›Paper›PMID 27830092›Full record

ArticleBone marrow research2016

Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.

Gunjan L Shah, Aaron Winn, Pei-Jung Lin, Andreas Klein, Kellie A Sprague, Hedy P Smith, Rachel Buchsbaum, Joshua T Cohen, Kenneth B Miller, Raymond Comenzo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gunjan L ShahAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Box 298 Avenue, New York, NY 10065, USA.ORCID 0000-0002-9977-0456
Aaron WinnCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., Box 63, Boston, MA 02111, USA.
Pei-Jung LinCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., Box 63, Boston, MA 02111, USA.
Andreas KleinDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA.
Kellie A SpragueDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA.
Hedy P SmithDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA.
Rachel BuchsbaumDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA.
Joshua T CohenCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., Box 63, Boston, MA 02111, USA.
Kenneth B MillerDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA.
Raymond ComenzoDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA.
Susan K ParsonsDivision of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA; Center for Health Solutions, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., Box 345, Boston, MA 02111, USA.

Funding

RESEARCH TRAINING IN ONCOLOGYT32CA009429 · NCI · TUFTS MEDICAL CENTER · PI EVENS, ANDREW M · 1985 to 2013
$2.8M
NCI NIH HHS T32 CA009429
6 · The paper itself

Abstract

Comorbidity is more common in older patients and can increase the cost of care by increasing toxicity. Using the SEER-Medicare database from 2000 to 2007, we examined the costs and life-year benefit of Auto-HSCT for MM patients over the age of 65 by evaluating the difference over time relative to comorbidity burden. One hundred ten patients had an Auto-HSCT in the early time period (2000-2003) and 160 in the late time period (2004-2007). Patients were divided by a Charlson Comorbidity Index (CCI) of 0 or greater than 1 (CCI1+). Median overall survival was 53.5 months for the late time period patients compared to 40.3 months for the early time period patients (

Identifiers

PMID27830092
PMCPMC5088316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.